Raj Airey

Director/Board Member at Cytovation AS

Health Technology

Consumer Services

Commercial Services

Profile

Raj Airey is currently a Director at Cytovation AS.
Previously, he worked as a Director & Chief Strategy Officer at SOM Innovation Biotech SA. He completed his undergraduate degree at the University of London.

Raj Airey active positions

Companies	Position	Start
Cytovation AS Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn.	Director/Board Member	-

All active positions of Raj Airey

Former positions of Raj Airey

Companies	Position	End
SOM Innovation Biotech SA SOM Innovation Biotech SA Pharmaceuticals: MajorHealth Technology SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.	Director/Board Member	-

See the detail of Raj Airey's experience

Training of Raj Airey

University of London

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Raj Airey's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
SOM Innovation Biotech SA SOM Innovation Biotech SA Pharmaceuticals: MajorHealth Technology SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain.	Health Technology
Cytovation AS Cytovation AS Miscellaneous Commercial ServicesCommercial Services Cytovation AS is a Norwegian clinical stage immune-oncology company that focuses on developing Cypep-1, a first-in-class immunotherapy that targets the cell membrane of tumor cells. The company is a spin-off from the University of Bergen and is headquartered in Bergen, Norway. Cypep-1 has a unique mechanism of action that eliminates cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination. Cytovation develops treatments for solid tumors in oncology and rare diseases, building on over 15 years of cutting-edge research. The CEO is Lars Prestegarden, and the company was founded by Rolf Bjerkvig, Per Eystein, and Stein Christian Mohn.	Commercial Services